Health and Healthcare

Merck : MRK

All Merck Articles

1084 Articles

Chris Lange | Jan 11, 2019 at 9:50 AM EST

Major Pharma Sees Fading Short Interest

The December 31 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Jan 3, 2019 at 8:45 AM EST

Merck’s Blockbuster Cancer Drug Keytruda Wins Multiple Approvals in Japan

Merck shares were relatively unchanged early on Thursday after the firm announced that its blockbuster drug Keytruda reported a series…

Jon C. Ogg | Jan 2, 2019 at 7:55 AM EST

Bull/Bear Outlook for 2019: How All 30 Dow Stocks Could Take the Market Up to 28,000

See why preliminary 2019 consensus-based forecasting has offered up a likely target of 28,000 on the Dow Jones industrial average…

Jon C. Ogg | Dec 31, 2018 at 2:20 PM EST

Meet the 2019 Dogs of the Dow

Investors love their dividends. So 24/7 Wall St. has tracked the Dogs of the Dow strategy for years now.

Chris Lange | Dec 27, 2018 at 10:00 AM EST

Short Sellers Hike Bets in Major Pharma Stocks

The December 14 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Dec 12, 2018 at 9:50 AM EST

Major Pharma Stocks See a Surge in Short Interest

The November 30 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Dec 8, 2018 at 7:20 AM EST

Major Health Care Catalysts Coming by the End of 2018

24/7 Wall St. takes a look at what is coming up in the FDA calendar regarding biotech and pharmaceutical companies…

Chris Lange | Nov 28, 2018 at 9:00 AM EST

Short Sellers Hike Their Bets in Major Pharma Stocks

The November 15 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Nov 12, 2018 at 10:10 AM EST

Short Sellers Pull Back on Major Pharma — With 1 Big Exception

The October 31 short interest data have been compared with the previous figures, and short interest in most of these…

Trey Thoelcke | Nov 12, 2018 at 6:50 AM EST

The 6 Most Shorted NYSE Stocks

Judging by the most shorted stocks traded on the New York Stock Exchange between the October 15 and October 31…

Paul Ausick | Nov 3, 2018 at 8:04 AM EDT

Merck Takes Over as Dow’s Top-Performing Dow Stock

Drugmaker Merck wrestled away from Apple the top ranking last week as the best performing stock among the Dow 30.

Paul Ausick | Nov 2, 2018 at 4:01 PM EDT

Apple, Intel Tank the Dow Friday

Apple, Intel, Pfizer, and Merck were the worst performing Dow stocks on Friday.

Chris Lange | Oct 31, 2018 at 10:55 AM EDT

Merck Wins Yet Again With New Keytruda Approval

Merck shares were up slightly on Wednesday after the pharma giant gave another key update for its KEYTRUDA line. The…

Douglas A. McIntyre | Oct 31, 2018 at 6:50 AM EDT

Dow Stars Apple and Merck Up Over 25%

Many market experts worry that poor earnings and a slowing economy could beat down the market between now and the…

Lee Jackson | Oct 27, 2018 at 9:55 AM EDT

5 Stocks to Move to Now If You Fear a Total Market Crash

What makes sense for investors now is safe stocks that pay dividends and provide products or services that will continue…

1 … 18 19 20 21 22 … 73

Merck : MRK

All Merck Articles

Major Pharma Sees Fading Short Interest

Merck’s Blockbuster Cancer Drug Keytruda Wins Multiple Approvals in Japan

Bull/Bear Outlook for 2019: How All 30 Dow Stocks Could Take the Market Up to 28,000

Meet the 2019 Dogs of the Dow

Short Sellers Hike Bets in Major Pharma Stocks

Major Pharma Stocks See a Surge in Short Interest

Major Health Care Catalysts Coming by the End of 2018

Short Sellers Hike Their Bets in Major Pharma Stocks

Short Sellers Pull Back on Major Pharma — With 1 Big Exception

The 6 Most Shorted NYSE Stocks

Merck Takes Over as Dow’s Top-Performing Dow Stock

Apple, Intel Tank the Dow Friday

Merck Wins Yet Again With New Keytruda Approval

Dow Stars Apple and Merck Up Over 25%

5 Stocks to Move to Now If You Fear a Total Market Crash

Skip ARKK’s Moonshots: This Fund Owns the AI Software Winners for 0.45%

NVIDA Vs. Tesla: Tesla Jumps as It Finally Fulfills Decade-Old Promise So Buy Nvidia Instead

The Dividend Growth Plan That Leaves High-Yield Stocks Behind

The Dividend Growth Plan That Leaves High-Yield Stocks Behind

"Bro, 3 Years and the Finances Are Separate?": Caleb Hammer Confronts Married Couple With 4 Kids and a Past-Due Mortgage

Skip ARKK’s Moonshots: This Fund Owns the AI Software Winners for 0.45%

NVIDA Vs. Tesla: Tesla Jumps as It Finally Fulfills Decade-Old Promise So Buy Nvidia Instead

Merck : MRK

All Merck Articles

Major Pharma Sees Fading Short Interest

Merck’s Blockbuster Cancer Drug Keytruda Wins Multiple Approvals in Japan

Bull/Bear Outlook for 2019: How All 30 Dow Stocks Could Take the Market Up to 28,000

Meet the 2019 Dogs of the Dow

Short Sellers Hike Bets in Major Pharma Stocks

Major Pharma Stocks See a Surge in Short Interest

Major Health Care Catalysts Coming by the End of 2018

Short Sellers Hike Their Bets in Major Pharma Stocks

Short Sellers Pull Back on Major Pharma — With 1 Big Exception

The 6 Most Shorted NYSE Stocks

Merck Takes Over as Dow’s Top-Performing Dow Stock

Apple, Intel Tank the Dow Friday

Merck Wins Yet Again With New Keytruda Approval

Dow Stars Apple and Merck Up Over 25%

5 Stocks to Move to Now If You Fear a Total Market Crash

Skip ARKK’s Moonshots: This Fund Owns the AI Software Winners for 0.45%

NVIDA Vs. Tesla: Tesla Jumps as It Finally Fulfills Decade-Old Promise So Buy Nvidia Instead

The Dividend Growth Plan That Leaves High-Yield Stocks Behind

Featured Reads

The Dividend Growth Plan That Leaves High-Yield Stocks Behind

"Bro, 3 Years and the Finances Are Separate?": Caleb Hammer Confronts Married Couple With 4 Kids and a Past-Due Mortgage